Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2007

01.03.2007 | Original Paper

Elevated Expression of Autocrine Motility Factor Receptor Correlates with Overexpression of RhoC and Indicates Poor Prognosis in Hepatocellular Carcinoma

verfasst von: Wei Wang, Lian-Yue Yang, Zhi-Li Yang, Ji-Xiang Peng, Jie-Quan Yang

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Our previous study identified RhoC as an invasion and metastasis marker in hepatocellular carcinoma patients. Recent document suggested RhoGTPase is required for autocrine motility factor signaling. In this study, we questioned whether there is a correlation between expression of autocrine motility factor receptor and RhoC. Furthermore, we questioned whether elevated expression of autocrine motility factor correlates with metastasis and poor prognosis of HCC. The mRNA expression level of AMFR and RhoC were examined by RT-PCR in 25 cases of HCC and pericarcinomatous liver tissues (PCLT). In addition, the correlation between the expression level of AMFR and clinical pathologic parameters was analyzed. Furthermore, follow-up information was collected to evaluate the prognostic value of AMFR for HCC patients. Our results showed that the expression of AMFR and RhoC significantly increased in HCC compared with PCLT; extrahepatic metastatic lesions expressed significantly higher levels of AMFR and RhoC than corresponding intrahepatic HCC tissues. There is a highly significant correlation of AMFR expression levels with tumor vein invasion, number of tumor nodes, and tumor stage. Anticipatively, positive correlation was observed between mRNA expression of AMFR and RhoC gene. Furthermore, the HCC patients with high-expression of AMFR had significant high recurrence/metastasis and shorter survival than those with low-expression of AMFR. Together, our findings suggested a strong correlation between the expression of AMFR and RhoC and also a correlation between overexpression of them and invasion and metastasis of HCC. Furthermore, our data indicated AMFR as a potential prognosis for HCC.
Literatur
1.
Zurück zum Zitat Tung P, Poon R, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24CrossRef Tung P, Poon R, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24CrossRef
2.
Zurück zum Zitat Murray CJ, Lopez AD (1997) Mortality by cause for eight regions of the world. Global Burden of Disease Study. Lancet 349:1269–1276PubMedCrossRef Murray CJ, Lopez AD (1997) Mortality by cause for eight regions of the world. Global Burden of Disease Study. Lancet 349:1269–1276PubMedCrossRef
4.
Zurück zum Zitat Makuuchi M, Takayama T, Kubota K, Kimura W, Midorikawa Y, Miyagawa S, Kawasaki S (1998) Hepatic resection for hepatocellular carcinoma: Japanese experience. Hepatogastroenterology 45:1267–1274PubMed Makuuchi M, Takayama T, Kubota K, Kimura W, Midorikawa Y, Miyagawa S, Kawasaki S (1998) Hepatic resection for hepatocellular carcinoma: Japanese experience. Hepatogastroenterology 45:1267–1274PubMed
5.
Zurück zum Zitat Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 229:322–330PubMedCrossRef Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J (1999) Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 229:322–330PubMedCrossRef
6.
Zurück zum Zitat Poon TPR, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24CrossRef Poon TPR, Fan ST, Wong J (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232:10–24CrossRef
7.
Zurück zum Zitat Yamaguchi H, Wyckoff J, Condeelis J (2005) Cell migration in tumors. Curr Opin Cell Biol 17:559–564PubMedCrossRef Yamaguchi H, Wyckoff J, Condeelis J (2005) Cell migration in tumors. Curr Opin Cell Biol 17:559–564PubMedCrossRef
8.
Zurück zum Zitat Yamazaki D, Kurisu S, Takenawa T (2005) Regulation of cancer cell motility through actin reorganization. Cancer Sci 96:379–386PubMedCrossRef Yamazaki D, Kurisu S, Takenawa T (2005) Regulation of cancer cell motility through actin reorganization. Cancer Sci 96:379–386PubMedCrossRef
9.
Zurück zum Zitat Silletti S, Watanabe H, Hogan V, Nabi IR, Raz A (1991) Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res 51:3507–3511PubMed Silletti S, Watanabe H, Hogan V, Nabi IR, Raz A (1991) Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res 51:3507–3511PubMed
10.
Zurück zum Zitat Watanabe H, Carmi P, Hogan V, Raz T, Silletti S, Nabi IR, Raz A (1991) Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 266:13442–13448PubMed Watanabe H, Carmi P, Hogan V, Raz T, Silletti S, Nabi IR, Raz A (1991) Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J Biol Chem 266:13442–13448PubMed
11.
Zurück zum Zitat Stracke ML, Guirguis R, Liotta LA, Schiffmann E (1987) Pertussis toxin inhibits stimulated motility independently of the adenylate cyclase pathway in human melanoma cells. Biochem Biophys Res Commun 146:339–345PubMedCrossRef Stracke ML, Guirguis R, Liotta LA, Schiffmann E (1987) Pertussis toxin inhibits stimulated motility independently of the adenylate cyclase pathway in human melanoma cells. Biochem Biophys Res Commun 146:339–345PubMedCrossRef
12.
Zurück zum Zitat Tsutsumi S, Gupta SK, Hogan V, Collard JG, Raz A (2002) Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res 62:4484–4490PubMed Tsutsumi S, Gupta SK, Hogan V, Collard JG, Raz A (2002) Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res 62:4484–4490PubMed
13.
14.
Zurück zum Zitat Van Aelst L, D'Souza-Schorey C (1997) Rho GTPases and signaling networks. Genes Dev 11:2295–2322PubMed Van Aelst L, D'Souza-Schorey C (1997) Rho GTPases and signaling networks. Genes Dev 11:2295–2322PubMed
16.
Zurück zum Zitat Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukumoto M (1998) Overexpression of RhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77:147–152PubMed Suwa H, Ohshio G, Imamura T, Watanabe G, Arii S, Imamura M, Narumiya S, Hiai H, Fukumoto M (1998) Overexpression of RhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer 77:147–152PubMed
17.
Zurück zum Zitat Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61:2129–2137PubMed Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y (2001) Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 61:2129–2137PubMed
18.
Zurück zum Zitat Wang W, Yang LY, Yang ZL, Huang GW, Lu WQ (2003) Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol 9:1950–1953PubMed Wang W, Yang LY, Yang ZL, Huang GW, Lu WQ (2003) Expression and significance of RhoC gene in hepatocellular carcinoma. World J Gastroenterol 9:1950–1953PubMed
19.
Zurück zum Zitat Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, Liu HL (2004) Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90:2349–2355PubMed Wang W, Yang LY, Huang GW, Lu WQ, Yang ZL, Yang JQ, Liu HL (2004) Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer 90:2349–2355PubMed
20.
Zurück zum Zitat Yang LY, Wang W, Peng JX, Yang JQ, Huang GW (2004) Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma. World J Gastroenterol 10:3569–3573PubMed Yang LY, Wang W, Peng JX, Yang JQ, Huang GW (2004) Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma. World J Gastroenterol 10:3569–3573PubMed
21.
Zurück zum Zitat Charalabopoulos K, Mittari E, Karakosta A, Golias C, Batistatou A (2005) Integrins adhesion molecules and some of their ligands in laryngeal cancer. Exp Oncol 27:86–90PubMed Charalabopoulos K, Mittari E, Karakosta A, Golias C, Batistatou A (2005) Integrins adhesion molecules and some of their ligands in laryngeal cancer. Exp Oncol 27:86–90PubMed
22.
Zurück zum Zitat Gogali A, Charalabopoulos K, Constantopoulos S (2004) Integrin receptors in primary lung cancer. Exp Oncol 26:106–110PubMed Gogali A, Charalabopoulos K, Constantopoulos S (2004) Integrin receptors in primary lung cancer. Exp Oncol 26:106–110PubMed
23.
Zurück zum Zitat Donald CD, Cooper CR, Harris-Hooker S, Emmett N, Scanlon M, Cooke DB (2001) Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer. Cell Mol Biol (Noisy-le-grand) 47:1033–1038 Donald CD, Cooper CR, Harris-Hooker S, Emmett N, Scanlon M, Cooke DB (2001) Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer. Cell Mol Biol (Noisy-le-grand) 47:1033–1038
24.
Zurück zum Zitat Shimizu K, Tani M, Watanabe H, Nagamachi Y, Niinaka Y, Shiroishi T, Ohwada S, Raz A, Yokota J (1999) The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 456:295–300PubMedCrossRef Shimizu K, Tani M, Watanabe H, Nagamachi Y, Niinaka Y, Shiroishi T, Ohwada S, Raz A, Yokota J (1999) The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 456:295–300PubMedCrossRef
25.
Zurück zum Zitat Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E (1990) The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Invest 8:351–356PubMed Baumann M, Kappl A, Lang T, Brand K, Siegfried W, Paterok E (1990) The diagnostic validity of the serum tumor marker phosphohexose isomerase (PHI) in patients with gastrointestinal, kidney, and breast cancer. Cancer Invest 8:351–356PubMed
26.
Zurück zum Zitat Ridley AJ (2001) RhoGTPases and cell migration. J Cell Sci 114:2713–2722PubMed Ridley AJ (2001) RhoGTPases and cell migration. J Cell Sci 114:2713–2722PubMed
27.
Zurück zum Zitat Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535PubMedCrossRef Clark EA, Golub TR, Lander ES, Hynes RO (2000) Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532–535PubMedCrossRef
Metadaten
Titel
Elevated Expression of Autocrine Motility Factor Receptor Correlates with Overexpression of RhoC and Indicates Poor Prognosis in Hepatocellular Carcinoma
verfasst von
Wei Wang
Lian-Yue Yang
Zhi-Li Yang
Ji-Xiang Peng
Jie-Quan Yang
Publikationsdatum
01.03.2007
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2007
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9479-4

Weitere Artikel der Ausgabe 3/2007

Digestive Diseases and Sciences 3/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.